Empagliflozin reduces real-world heart failure hospitalization in type 2 diabetes

Compared with DPP-IV inhibitors, the SGLT2 inhibitor empagliflozin was associated with a 44% relative risk reduction in hospitalization for heart failure in people with type 2 diabetes with and without established cardiovascular disease, according to initial results from the EMPRISE study announced by Boehringer Ingelheim and Eli Lilly.

The early findings, a real-world analysis of approximately 35,000 people with type 2 diabetes between August 2014 and September 2016, support data from the landmark EMPA-REG CV outcomes trail, which demonstrated a 35% relative risk reduction in hospitalization for heart failure in people with type 2 diabetes and established CVD when compared with placebo. The initial EMPA-REG findings were presented in September 2015 and reported by Endocrine Today.

“With more than a million hospital admissions for heart failure in the U.S. every year, it’s important to understand whether the relative risk reduction in hospitalization for heart failure seen in the EMPA-REG Outcome trial translates into routine clinical care,” Elisabetta Patorno, MD, DrPH, of the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital and assistant professor of medicine, Harvard Medical School, said in a press release. “These first results from the EMPRISE study show that empagliflozin [Jardiance] is associated with a reduction in hospitalization for heart failure, and the effect is consistent in people with type 2 diabetes with and without history of cardiovascular disease.”

Leave a Reply

Your email address will not be published. Required fields are marked *